Pereira Lab
@cellreprolab.bsky.social
Cell Reprogramming in Hematopoiesis and Immunity, Lund University, Sweden. Tweets by Filipe Pereira (signed FP) and Malavika Nair (for Pereira lab). https://pereiralab.com/
1/4 Great to share that our lab was awarded a research grant from the Mats Paulsson Foundation for Research, Innovation and Societal Development for the project “Advancing Reactive Tumor-Infiltrating Lymphocyte Therapy with Cellular Reprogramming”.
October 24, 2025 at 2:47 PM
1/4 Great to share that our lab was awarded a research grant from the Mats Paulsson Foundation for Research, Innovation and Societal Development for the project “Advancing Reactive Tumor-Infiltrating Lymphocyte Therapy with Cellular Reprogramming”.
1/2 Sharing exciting news! ✨
Our recently published paper “Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity” has been selected for the cover of the October issue of Immunity!
@cp-immunity.bsky.social
Our recently published paper “Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity” has been selected for the cover of the October issue of Immunity!
@cp-immunity.bsky.social
October 14, 2025 at 3:41 PM
1/2 Sharing exciting news! ✨
Our recently published paper “Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity” has been selected for the cover of the October issue of Immunity!
@cp-immunity.bsky.social
Our recently published paper “Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity” has been selected for the cover of the October issue of Immunity!
@cp-immunity.bsky.social
2/2 Yet, dendritic cells had another go with Abigail Altman, who won the Best Poster Award with "Transcription factor blueprints underlying dendritic cell diversity", now out in Immunity (www.cell.com/immunity/ful.... Congrats to both! It's great to have our contributions recognized!
September 17, 2025 at 1:08 PM
2/2 Yet, dendritic cells had another go with Abigail Altman, who won the Best Poster Award with "Transcription factor blueprints underlying dendritic cell diversity", now out in Immunity (www.cell.com/immunity/ful.... Congrats to both! It's great to have our contributions recognized!
1/2 Celebrating a double win!✨ Yesterday, at the Lund Stem Cell Center (LSCC) retreat, Ervin Ascic was awarded the Article of the Year Award with our Science paper "In vivo dendritic cell reprogramming for cancer immunotherapy" (www.science.org/doi/10.1126/...)
September 17, 2025 at 1:06 PM
1/2 Celebrating a double win!✨ Yesterday, at the Lund Stem Cell Center (LSCC) retreat, Ervin Ascic was awarded the Article of the Year Award with our Science paper "In vivo dendritic cell reprogramming for cancer immunotherapy" (www.science.org/doi/10.1126/...)
We are proud to announce that Ervin Ascic successfully defended his PhD yesterday – with the special honor of Nobel Laureate James Allison as opponent! ✨
Ervin’s work makes a strong contribution, showing that in vivo dendritic cell reprogramming is paving the way toward the clinic.
Ervin’s work makes a strong contribution, showing that in vivo dendritic cell reprogramming is paving the way toward the clinic.
September 5, 2025 at 8:29 AM
We are proud to announce that Ervin Ascic successfully defended his PhD yesterday – with the special honor of Nobel Laureate James Allison as opponent! ✨
Ervin’s work makes a strong contribution, showing that in vivo dendritic cell reprogramming is paving the way toward the clinic.
Ervin’s work makes a strong contribution, showing that in vivo dendritic cell reprogramming is paving the way toward the clinic.
13/17 🧩 Our results propose that ETS–IRF pairwise interactions constitute the foundation upon which any DC identity may be built and help define the drivers of DC divergence, advancing our understanding of DC specification and heterogeneity.
August 29, 2025 at 4:20 PM
13/17 🧩 Our results propose that ETS–IRF pairwise interactions constitute the foundation upon which any DC identity may be built and help define the drivers of DC divergence, advancing our understanding of DC specification and heterogeneity.
12/17 ⚖️ Surviving mice remained tumor-free upon rechallenge, showing durable immune memory. This finding points toward patient-tailored DC subsets as a new immunotherapy avenue.
August 29, 2025 at 4:20 PM
12/17 ⚖️ Surviving mice remained tumor-free upon rechallenge, showing durable immune memory. This finding points toward patient-tailored DC subsets as a new immunotherapy avenue.
11/17 🐭 Importantly, in melanoma (YUMM1.7) and breast cancer (EO771), in vivo reprogramming towards different iDC subsets drove orthogonal anti-tumor responses, mirroring the natural DC responsiveness on these tumors.
August 29, 2025 at 4:19 PM
11/17 🐭 Importantly, in melanoma (YUMM1.7) and breast cancer (EO771), in vivo reprogramming towards different iDC subsets drove orthogonal anti-tumor responses, mirroring the natural DC responsiveness on these tumors.
10/17 💉 In B16 melanoma tumor models, adoptive transfer of iDCs slowed growth and improved survival through distinct mechanisms: iDC2s boosted CD8+ and CD4+ T cells; iLDCs promoted myeloid infiltration.
August 29, 2025 at 4:18 PM
10/17 💉 In B16 melanoma tumor models, adoptive transfer of iDCs slowed growth and improved survival through distinct mechanisms: iDC2s boosted CD8+ and CD4+ T cells; iLDCs promoted myeloid infiltration.
9/17 ⚙️ Mechanistically, each TF triad had different chromatin engagement modes and co-bound subset-specific genes early on, showing that DC subset divergence is set in motion at the very start of reprogramming.
August 29, 2025 at 4:17 PM
9/17 ⚙️ Mechanistically, each TF triad had different chromatin engagement modes and co-bound subset-specific genes early on, showing that DC subset divergence is set in motion at the very start of reprogramming.
8/17 ⚔️ Functionally, iDC2s resembled inflammatory cDC2Bs with features of interferon-stimulated cDC2s, activating CD8+ T cells via antigen uptake, processing, and cross-presentation, demonstrating real immune potential.
August 29, 2025 at 4:17 PM
8/17 ⚔️ Functionally, iDC2s resembled inflammatory cDC2Bs with features of interferon-stimulated cDC2s, activating CD8+ T cells via antigen uptake, processing, and cross-presentation, demonstrating real immune potential.
7/17 🧪 iLDCs expressed an immature pDC gene signature but with a distinct, pro-inflammatory profile. Adding IRF4 to SII boosted IFN-β secretion nearly 5-fold, showing potential for interferon secretion.
August 29, 2025 at 4:16 PM
7/17 🧪 iLDCs expressed an immature pDC gene signature but with a distinct, pro-inflammatory profile. Adding IRF4 to SII boosted IFN-β secretion nearly 5-fold, showing potential for interferon secretion.
6/17 🎯 iDCs showed subset-specific phenotypes (CLEC12A & SIRPα for PIP; LY6C & B220 for SII) without macrophage or lymphoid markers. PIP-induced cells (iDC2s) shared key cDC2 genes, and SII-induced cells (iLDCs) expressed many pDC genes but lacked some hallmarks (Siglech, Ly6D).
August 29, 2025 at 4:16 PM
6/17 🎯 iDCs showed subset-specific phenotypes (CLEC12A & SIRPα for PIP; LY6C & B220 for SII) without macrophage or lymphoid markers. PIP-induced cells (iDC2s) shared key cDC2 genes, and SII-induced cells (iLDCs) expressed many pDC genes but lacked some hallmarks (Siglech, Ly6D).
5/17 🔀 Both combinations rely on an ETS + IRF pair (PU.1/IRF4 or SPIB/IRF8) to prime DC identity. The third factor (PRDM1 or IKZF2) directs the subtype-specific program in induced dendritic cells (iDCs).
August 29, 2025 at 4:15 PM
5/17 🔀 Both combinations rely on an ETS + IRF pair (PU.1/IRF4 or SPIB/IRF8) to prime DC identity. The third factor (PRDM1 or IKZF2) directs the subtype-specific program in induced dendritic cells (iDCs).
4/17 Screening in mouse embryonic fibroblasts revealed 2 key combos: PIP (PU.1, IRF4, PRDM1) activated Clec9a reporter & CD11b expression showing cDC2-like cell programming; SII (SPIB, IRF8, IKZF2) activated the Clec9a & hCD2 lymphoid reporters & BST2 expression- pDC-like cell
August 29, 2025 at 4:14 PM
4/17 Screening in mouse embryonic fibroblasts revealed 2 key combos: PIP (PU.1, IRF4, PRDM1) activated Clec9a reporter & CD11b expression showing cDC2-like cell programming; SII (SPIB, IRF8, IKZF2) activated the Clec9a & hCD2 lymphoid reporters & BST2 expression- pDC-like cell
3/17 ⚓ We anchored the screen on known DC factors: PU.1, IRF8, and BATF3 induce cDC1s. When comparing their expression across subsets, PU.1 was enriched in cDC2s and IRF8 in pDCs, making them ideal starting points for discovering new “recipes”.
August 29, 2025 at 4:13 PM
3/17 ⚓ We anchored the screen on known DC factors: PU.1, IRF8, and BATF3 induce cDC1s. When comparing their expression across subsets, PU.1 was enriched in cDC2s and IRF8 in pDCs, making them ideal starting points for discovering new “recipes”.
2/17 💡 Our approach: a direct cellular reprogramming sequential “anchored screen” of 70 TFs to identify regulators that specify type 2 conventional DCs (cDC2s) and plasmacytoid DCs (pDCs).
August 29, 2025 at 4:13 PM
2/17 💡 Our approach: a direct cellular reprogramming sequential “anchored screen” of 70 TFs to identify regulators that specify type 2 conventional DCs (cDC2s) and plasmacytoid DCs (pDCs).
📢 New in @ImmunityCP: We have mapped the transcription factor “routes” that program two dendritic cell subsets opening paths for personalized #cancer #immunotherapy. Read it here: doi.org/10.1016/j.im...
Here is a summary of what we discovered 🧵:
Illustration by @azuravesta.bsky.social
Here is a summary of what we discovered 🧵:
Illustration by @azuravesta.bsky.social
August 29, 2025 at 4:11 PM
📢 New in @ImmunityCP: We have mapped the transcription factor “routes” that program two dendritic cell subsets opening paths for personalized #cancer #immunotherapy. Read it here: doi.org/10.1016/j.im...
Here is a summary of what we discovered 🧵:
Illustration by @azuravesta.bsky.social
Here is a summary of what we discovered 🧵:
Illustration by @azuravesta.bsky.social
12/17 ⚖️ Surviving mice remained tumor-free upon rechallenge, showing durable immune memory. This finding points toward patient-tailored DC subsets as a new immunotherapy avenue.
August 29, 2025 at 3:28 PM
12/17 ⚖️ Surviving mice remained tumor-free upon rechallenge, showing durable immune memory. This finding points toward patient-tailored DC subsets as a new immunotherapy avenue.
11/17 🐭 Importantly, in melanoma (YUMM1.7) and breast cancer (EO771), in vivo reprogramming towards different iDC subsets drove orthogonal anti-tumor responses, mirroring the natural DC responsiveness on these tumors.
August 29, 2025 at 3:27 PM
11/17 🐭 Importantly, in melanoma (YUMM1.7) and breast cancer (EO771), in vivo reprogramming towards different iDC subsets drove orthogonal anti-tumor responses, mirroring the natural DC responsiveness on these tumors.
10/17 💉 In B16 melanoma tumor models, adoptive transfer of iDCs slowed growth and improved survival through distinct mechanisms: iDC2s boosted CD8+ and CD4+ T cells; iLDCs promoted myeloid infiltration.
August 29, 2025 at 3:26 PM
10/17 💉 In B16 melanoma tumor models, adoptive transfer of iDCs slowed growth and improved survival through distinct mechanisms: iDC2s boosted CD8+ and CD4+ T cells; iLDCs promoted myeloid infiltration.
9/17 ⚙️ Mechanistically, each TF triad had different chromatin engagement modes and co-bound subset-specific genes early on, showing that DC subset divergence is set in motion at the very start of reprogramming.
August 29, 2025 at 3:25 PM
9/17 ⚙️ Mechanistically, each TF triad had different chromatin engagement modes and co-bound subset-specific genes early on, showing that DC subset divergence is set in motion at the very start of reprogramming.
8/17 ⚔️ Functionally, iDC2s resembled inflammatory cDC2Bs with features of interferon-stimulated cDC2s, activating CD8+ T cells via antigen uptake, processing, and cross-presentation, demonstrating real immune potential.
August 29, 2025 at 3:25 PM
8/17 ⚔️ Functionally, iDC2s resembled inflammatory cDC2Bs with features of interferon-stimulated cDC2s, activating CD8+ T cells via antigen uptake, processing, and cross-presentation, demonstrating real immune potential.
7/17 🧪 iLDCs expressed an immature pDC gene signature but with a distinct, pro-inflammatory profile. Adding IRF4 to SII boosted IFN-β secretion nearly 5-fold, showing potential for interferon secretion.
August 29, 2025 at 3:24 PM
7/17 🧪 iLDCs expressed an immature pDC gene signature but with a distinct, pro-inflammatory profile. Adding IRF4 to SII boosted IFN-β secretion nearly 5-fold, showing potential for interferon secretion.
6/17 🎯 iDCs showed subset-specific phenotypes (CLEC12A & SIRPα for PIP; LY6C & B220 for SII) without macrophage or lymphoid markers. PIP-induced cells (iDC2s) shared key cDC2 genes, and SII-induced cells (iLDCs) expressed many pDC genes but lacked some hallmarks (Siglech, Ly6D).
August 29, 2025 at 3:24 PM
6/17 🎯 iDCs showed subset-specific phenotypes (CLEC12A & SIRPα for PIP; LY6C & B220 for SII) without macrophage or lymphoid markers. PIP-induced cells (iDC2s) shared key cDC2 genes, and SII-induced cells (iLDCs) expressed many pDC genes but lacked some hallmarks (Siglech, Ly6D).